Skip to content
value.today
Protagonist Therapeutics Inc logo

Protagonist Therapeutics Inc

Total raised
$25 M
2 rounds on record
Latest round
$18 M
Jul 2015
First round on record
May 2013
Today
Went public
See the company page

Protagonist Therapeutics Inc is listed today as Protagonist Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Protagonist Therapeutics Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2015$18 MNo. 2$10 to $50 million

Protagonist Therapeutics Inc: Raise no. 2, Jul 2015

Investors in this round

9 investors had bought by the notice of Jul 24, 2015: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Protagonist Therapeutics Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$18 M of $40 M offered; $23 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dinesh V. Patel, PhD · Executive Officer, Director
  • Armen V. Shanafelt, Ph.D. · Director
  • Asish K. Xavier, Ph.D. · Director
  • Harold E. Selick, Ph.D. · Director
  • Michael K. Panaccio, Ph.D. · Director
  • Paul F. Truex · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director, or promoter will receive any payments from the proceeds of this offering.”

Signed by Dinesh V. Patel PhD, President/CEO. Source: SEC Form D, newest notice filed Jul 24, 2015. Read the notice at the SEC.

equitySEC
May 2013$7 MNo. 1$2 to $10 million

Protagonist Therapeutics Inc: Raise no. 1, May 2013

Investors in this round

4 investors had bought by the notice of Jun 11, 2013: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Protagonist Therapeutics Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $18 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dinesh Patel, PhD · Executive Officer, Director
  • Armen Shanafelt · Director
  • Asish K. Xavier · Director
  • Harold Selick · Director
  • Nicholas Peace · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director, or promoter will receive any payments from the proceeds of this offering.”

Signed by Dinesh V. Patel PhD, President/CEO. Source: SEC Form D, newest notice filed Jun 11, 2013. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Protagonist Therapeutics, Inc., its revenue in fiscal 2025 came from these business segments: Single reportable segment $46.02 million (100%).

    Annual report (SEC XBRL) · Dec 2025

  • Protagonist Therapeutics Inc chose not to state its revenue in its newest notice of a funding round (Jul 2015).

    SEC Form D · Jul 2015

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2015

Products and services#

No products or services of Protagonist Therapeutics Inc are on record.

Investors#

5 named in official filings. Open an investor to see everything it has backed.

Investors in Protagonist Therapeutics Inc
InvestorKindAmountRoundRoleSource
Canaan Partners X LLCFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner, director (Form 3, 2016)SEC Form 3
Canaan X L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner, director (Form 3, 2016)SEC Form 3
Johnson & Johnson Development Corp Et AlCompanynot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Lilly Ventures Fund I LLCVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2016)SEC Form 3
LV Management Group, LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2016)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 9 investors.

Largest shareholders today

Institutions holding Protagonist Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Protagonist Therapeutics Inc
NameRoleNamed in
Dinesh V. Patel, PhDExecutive officerJul 2015
Dinesh Patel, PhDExecutive officerJun 2013
Armen V. Shanafelt, Ph.D.DirectorJul 2015
Asish K. Xavier, Ph.D.DirectorJul 2015
Dinesh V. Patel, PhDDirectorJul 2015
Harold E. Selick, Ph.D.DirectorJul 2015
Michael K. Panaccio, Ph.D.DirectorJul 2015
Paul F. TruexDirectorJul 2015
Armen ShanafeltDirectorJun 2013
Asish K. XavierDirectorJun 2013
Dinesh Patel, PhDDirectorJun 2013
Harold SelickDirectorJun 2013
Nicholas PeaceDirectorJun 2013

Went public since 2016. Its SEC number is that of a company listed on a stock exchange.